Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio10.98
Quick Ratio10.98
Price-To-Earnings
Trailing P/E Ratio-1.11
Forward P/E Ratio-2.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.67 million
Price / Sales15.96
Cash FlowN/A
Price / CashN/A
Book Value$2.53 per share
Price / Book1.15
Profitability
EPS (Most Recent Fiscal Year)($2.63)
Net Income$-114,750,000.00
Net Margins-421.64%
Return on Equity-67.34%
Return on Assets-59.14%
Miscellaneous
Employees78
Outstanding Shares52,860,000
Market Cap$159.10 million
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.18. The biopharmaceutical company earned $11.58 million during the quarter, compared to analysts' expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. View Tetraphase Pharmaceuticals' Earnings History.
When is Tetraphase Pharmaceuticals' next earnings date?
What price target have analysts set for TTPH?
9 brokerages have issued 12-month target prices for Tetraphase Pharmaceuticals' stock. Their predictions range from $3.00 to $10.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $6.8571 in the next year. This suggests a possible upside of 134.8% from the stock's current price. View Analyst Price Targets for Tetraphase Pharmaceuticals.
What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tetraphase Pharmaceuticals.
What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?
Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (8/16/2018)
- 2. Needham & Company LLC analysts commented, "Tetraphase reported 2Q18 financial results yesterday and we spoke with mgmt for a corporate update. As a reminder, the EMA CHMP issued a positive opinion for Xerava last week. Approval in Europe is likely in Sept or Oct 2018. Xerava is also under review by the FDA, w/ an 8/27/18 PDFUA date. We expect approval. Mgmt has guided for launch in the U.S. in early 4Q18 and in UK and Germany in early 2019. Maintain HOLD, given our concerns over peak sales potential. Although Xerava is an effective antibiotic, we believe the commercial opportunity for new antibiotics in the IV Gram-negative hospital market may be modest." (8/3/2018)
- 3. HC Wainwright analysts commented, "and Likely Commercial Uptake in cIAI; Affirm Buy Stock Data 05/03/2018 Price $3.15 Exchange NASDAQ Price Target $6.00 52-Week High $8.75 52-Week Low $2.05 Enterprise Value (M) $45.3 Market Cap (M) $163 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 1,678,640 Short Interest (M) 3.41 Shares Outstanding (M): Figure shown is as of May 2, 2018. Balance Sheet Metrics Cash (M) $117.7 Total Debt (M) $0.0 Total Cash/Share $2.28 Book Value/Share $1.93 Cash (M): Figure shown is as of March 31, 2018. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.46) (0.79) (0.42)A 2Q (0.47) (0.83) (0.37) 3Q (0.58) (0.63) (0.31) 4Q (0.61) (0.46) (0.24) FY (2.11) (2.63) (1.32) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 2.0 1.5 1.9A 2Q 1.2 1.6 2.0 3Q 0.9 4.1 1.8 4Q 1.1 2.5 1.5 FY 5.1 9.7 7.2 10 8 6 4 2 0 MAY-17 SEP-17 JAN-18 MAY-18 20 15 10 5 0 Vol. (mil) Price Making it official." (5/4/2018)
Are investors shorting Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,542,272 shares, an increase of 49.4% from the August 15th total of 1,701,588 shares. Based on an average daily volume of 1,628,594 shares, the short-interest ratio is presently 1.6 days. Currently, 4.9% of the company's stock are sold short. View Tetraphase Pharmaceuticals' Current Options Chain.
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include Kura Oncology (KURA), ANI Pharmaceuticals (ANIP), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Vectura Group (VEGPF), Rigel Pharmaceuticals (RIGL), ChemoCentryx (CCXI), Beyondspring (BYSI), OptiNose (OPTN), ZEALAND PHARMA/S (ZEAL), AC Immune (ACIU), TIGENIX/S (TIG), Stemline Therapeutics (STML), Theratechnologies (THERF) and Prothena (PRTA).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 59)
- Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 53)
- Dr. Jacques Dumas, Chief Scientific Officer (Age 52)
- Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 47)
- Mr. Larry G. Edwards, Chief Operating Officer (Age 46)
Has Tetraphase Pharmaceuticals been receiving favorable news coverage?
Media stories about TTPH stock have been trending somewhat positive on Friday, Accern reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Tetraphase Pharmaceuticals.
Who are Tetraphase Pharmaceuticals' major shareholders?
Tetraphase Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.89%), Dimensional Fund Advisors LP (4.16%), Northern Trust Corp (2.01%), Renaissance Technologies LLC (1.18%), Millennium Management LLC (0.56%) and Bank of New York Mellon Corp (0.56%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.
Which major investors are selling Tetraphase Pharmaceuticals stock?
Which major investors are buying Tetraphase Pharmaceuticals stock?
TTPH stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Millennium Management LLC, Royce & Associates LP, BlackRock Inc., Canada Pension Plan Investment Board, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Northern Trust Corp. View Insider Buying and Selling for Tetraphase Pharmaceuticals.
How do I buy shares of Tetraphase Pharmaceuticals?
Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $2.92.
How big of a company is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals has a market capitalization of $159.10 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe.
How can I contact Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]
MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
